HTA Council Recommendation (as of 13 April 2023) The HTA Council does not recommend government financing of cerebrolysin 215.2mg/mL , 10 mL ampule for IV infusion, in combination with rehabilitation, for the treatment of adults post-ischemic stroke, thus its non-inclusion in the Philippine National Formulary. (See below for more details) Relevant Information Evidence and Relevant continue reading : Cerebrolysin [215.2 mg/mL, 10mL ampule for IV infusion] for the treatment of post-ischemic stroke
Ceftaroline Fosamil (600 mg powder for concentrate for solution for injection) in the Treatment of Community-Acquired Pneumonia (CAP) in Children
HTA Council Recommendation (as of 14 May 2025) The HTA Council does not recommend the government financing of ceftaroline fosamil for the treatment of community-acquired pneumonia (CAP) in the pediatric population. (See below for more details) Relevant Information Evidence and Relevant Documents Assessment History Back to Assessments Page
Factor VIII Inhibitor bypassing activity powder solution for infusion (IV) for treatment of bleeding events for hemophilia B patients with inhibitors
HTA Council Recommendation (as of 29 April 2025) The HTA Council recommends the government financing of Factor VIII Inhibitor bypassing activity powder solution for infusion (IV) for treatment of bleeding events for hemophilia B patients with inhibitors. (See below for more details) Relevant Information Evidence and Relevant Documents Assessment History Back to Assessments Page
Factor VIII Inhibitor bypassing activity powder solution for infusion (IV) for treatment of bleeding events for hemophilia A patients with inhibitors
HTA Council Recommendation (as of 29 April 2025) The HTA Council recommends the government financing of Factor VIII Inhibitor bypassing activity powder solution for infusion (IV) for treatment of bleeding events for hemophilia A patients with inhibitors. (See below for more details) Relevant Information Evidence and Relevant Documents Assessment History Back to Assessments Page
Plasma-derived Coagulation Factor VIII for treatment of bleeding in the pediatric population with hemophilia A
HTA Council Recommendation (as of 29 April 2025) The HTA Council recommends the government financing of Plasma-derived Coagulation Factor VIII for treatment of bleeding in the pediatric population with hemophilia A. (See below for more details) Relevant Information Evidence and Relevant Documents Assessment History Assessments Page